Acerca de
Revise. Cambie. Controle. Colesterol™

El colesterol y las enfermedades cardiovasculares

Dos médicos y un enfermero hablando

An estimated 126.9 million US adults are living with at least one type of cardiovascular disease (CVD)1, and by 2035, persons with CVD will account for nearly 45% of the adult US population.

The accumulation low-density lipoproteins (LDL-C) can lead to plaque deposits and atherosclerosis, increasing the risk for heart attack and stroke. Sadly, LDL-C is on the rise. Globally in 2020, there were 4.51 million deaths attributable to high LDL-C, a 19% increase from 2010.

Recursos relacionados con el programa Revise. Cambie. Controle. Colesterol™ puede hacer que todo cambie


Latest Guideline Recommendations

Despite evidence promoting the efficacy of statin therapy for cholesterol management, longitudinal studies(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window) have confirmed that statin treatment rates were unchanged following the release of the 2013 ACC/AHA Guideline. The opportunity for a targeted blood cholesterol strategy gave rise to the most current ACC/AHA guideline, the 2018 Guideline on the Management of Blood Cholesterol(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window)(link opens in new window).

In the current guideline, new support for primary and secondary prevention of ASCVD was released that highlight the importance of identifying very-high risk atherosclerotic cardiovascular disease (ASCVD) patients, as well as intensification to non-statin agents such as ezetimibe and PCSK-9 inhibitors when clinically indicated. This model endeavors to provide clinicians with the algorithm-based tools to understand, treat, and control cholesterol for good.


Join Check. Change. Control. Cholesterol™

The AHA launched Check. Change. Control. Cholesterol to improve the identification and management of cholesterol across the nation. This national initiative aims to reduce the number of Americans who have heart attacks and strokes by urging medical practices, providers, and patients to screen and treat this important risk factor.

Check. Change. Control. Cholesterol supports physicians and care teams by offering access to the latest research, tools, and resources to reach and sustain cholesterol control rates among the adult patient population that they serve.

HCP with laptop

Join us!

Register now to enroll in the initiative and receive timely information about data submission and recognition opportunities.  Registration is available year-round.  


Logotipo de Amgen Cardiovascular


Amgen es un orgulloso promotor de la iniciativa Check. Change. Control. Cholesterol™ de la American Heart Association.